Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone

Respiration

Volumn 93, Issue 6, 2017, Pages 415-423

  Kreuter, Michael ^a,b   Spagnolo, Paolo ^c   Wuyts, Wim ^d   Renzoni, Elisabetta ^e   Koschel, Dirk ^f   Bonella, Francesco ^g   Maher, Toby M ^e   Kolb, Martin ^h   Weycker, Derek ⁱ   Kirchgässler, Klaus Uwe ^j   Costabel, Ulrich ^g  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Translational Lung Research Center   (Germany)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e ROYAL BROMPTON HOSPITAL   (United Kingdom)

^f Fachkrankenhaus Coswig   (Germany)

^g RUHRLANDKLINIK   (Germany)

^h MCMASTER UNIVERSITY   (Canada)

ⁱ POLICY ANALYSIS INC PAI   (United States)

^j F HOFFMANN LA ROCHE LTD   (Switzerland)

more..

Author keywords

Antacid therapy; Gastroesophageal reflux disease; Idiopathic pulmonary fibrosis; Pirfenidone; Progression free survival

Indexed keywords

ANTACID AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; OMEPRAZOLE; PIRFENIDONE; PROTON PUMP INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CONTROLLED STUDY; DEATH; DISEASE COURSE; DYSPEPSIA; EXERCISE TOLERANCE; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GASTRITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HIATUS HERNIA; HOSPITALIZATION; HUMAN; INCIDENCE; LUNG FUNCTION; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; POST HOC ANALYSIS; PRIORITY JOURNAL; SIX MINUTE WALK TEST; SURVIVAL RATE; ULCER; CAUSE OF DEATH; COMPLICATION; DISEASE EXACERBATION; LUNG FUNCTION TEST; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGY; STATISTICS AND NUMERICAL DATA; VITAL CAPACITY; WALK TEST;

AGED; ANTACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CAUSE OF DEATH; DISEASE PROGRESSION; EXERCISE TOLERANCE; FEMALE; GASTROESOPHAGEAL REFLUX; HISTAMINE H2 ANTAGONISTS; HOSPITALIZATION; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; MORTALITY; PROTON PUMP INHIBITORS; PYRIDONES; RESPIRATORY FUNCTION TESTS; SURVIVAL RATE; VITAL CAPACITY; WALK TEST;

EID: 85017714215     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000468546     Document Type: Article

References (35)

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Muller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schunemann HJ; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis: An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
2. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; INPULSIS Trial Investigators: Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071-2082.
3. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW; ASCEND Study Group: A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083-2092.
4. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM; CAPACITY Study Group: Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760-1769.
5. Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, Nakata K, Sato A, Takeuchi M, Raghu G, Kudoh S, Nukiwa T; Pirfenidone Clinical Study Group in Japan: Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 821-829.
6. Noble PW, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Lancaster L, Lederer DJ, Leff JA, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, King TE Jr: Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J 2016; 47: 243-253.
7. Kreuter M, Ehlers-Tenenbaum S, Palmowski K, Bruhwyler J, Oltmanns U, Muley T, Heussel CP, Warth A, Kolb M, Herth FJ: Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis. PLoS One 2016; 11:e0151425.
8. Katz PO, Gerson LB, Vela MF: Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2013; 108: 308-328.
9. Gribbin J, Hubbard R, Smith C: Role of diabetes mellitus and gastro-oesophageal reflux in the aetiology of idiopathic pulmonary fibrosis. Respir Med 2009; 103: 927-931.
10. Patti MG, Tedesco P, Golden J, Hays S, Hoopes C, Meneghetti A, Damani T, Way LW: Idiopathic pulmonary fibrosis: how often is it really idiopathic? J Gastrointest Surg 2005; 9: 1053-1056; discussion 1056-1058.
11. Raghu G, Freudenberger TD, Yang S, Curtis JR, Spada C, Hayes J, Sillery JK, Pope CE 2nd, Pellegrini CA: High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J 2006; 27: 136-142.
12. Tobin RW, Pope CE 2nd, Pellegrini CA, Emond MJ, Sillery J, Raghu G: Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 158: 1804-1808.
13. Ley B, Collard HR: Epidemiology of idiopathic pulmonary fibrosis. Clin Epidemiol 2013; 5: 483-492.
14. Sonnenberg A: Effects of environment and lifestyle on gastroesophageal reflux disease. Dig Dis 2011; 29: 229-234.
15. Gnanapandithan K, Popkin JH, Devadoss R, Martin K: Gastroesophageal reflux and idiopathic pulmonary fibrosis: a long term relationship. Respir Med Case Rep 2016; 17: 40-43.
16. Hershcovici T, Jha LK, Johnson T, Gerson L, Stave C, Malo J, Knox KS, Quan S, Fass R: Systematic review: the relationship between interstitial lung diseases and gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2011; 34: 1295-1305.
17. Wuyts WA, Collard HR: Gastroesophageal reflux in idiopathic pulmonary fibrosis: more than a gut feeling? Respiration 2016; 91: 1-2.
18. Kreuter M, Kirsten D, Bahmer T, Penzel R, Claussen M, Ehlers-Tenenbaum S, Muley T, Palmowski K, Eichinger M, Leider M, Herth FJ, Rabe KF, Bittmann I, Warth A: Screening for Helicobacter pylori in idiopathic pulmonary fibrosis lung biopsies. Respiration 2016; 91: 3-8.
19. Ghebre Y, Raghu G: Proton pump inhibitors in IPF: beyond mere suppression of gastric acidity. QJM 2016; 109: 577-579.
20. Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, Brozek JL, Collard HR, Cunningham W, Homma S, Johkoh T, Martinez FJ, Myers J, Protzko SL, Richeldi L, Rind D, Selman M, Theodore A, Wells AU, Hoogsteden H, Schunemann HJ; American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Association: An official ATS/ERS/ JRS/ALAT Clinical Practice Guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med 2015; 192:e3-e19.
21. Kreuter M, Wuyts W, Renzoni E, Koschel D, Maher TM, Kolb M, Weycker D, Spagnolo P, Kirchgaessler KU, Herth FJ, Costabel U: Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. Lancet Respir Med 2016; 4: 381-389.
22. Raghu G, Crestani B, Bailes Z, Schlenker-Herceg R, Costabel U: Effect of anti-acid medication on reduction in FVC decline with nintedanib. Eur Respir J 2015; 46(suppl 59):OA4502.
23. Wuyts WA, Bonella F, Costabel U, Cottin V, Kreuter M, Poletti V, Spagnolo P: An important step forward, but still a way to go. Am J Respir Crit Care Med 2016; 193: 340-341.
24. Raghu G: Anti-acid treatment in patients with IPF: interpret results from post-hoc, subgroup, and exploratory analyses with great caution. Lancet Respir Med 2016; 4:e46-e47.
25. Kreuter M, Wuyts W, Renzoni E, Koschel D, Maher T, Kolb M, Weycker D, Spagnolo P, Kirchgaessler K, Herth F, Costabel U: Antiacid treatment in patients with IPF: interpret results from post-hoc, subgroup, and exploratory analyses with great caution-authors' reply. Lancet Respir Med 2016; 4:e48.
26. Allison PD: Survival Analysis Using SAS: A Practical Guide, ed 2. Cary, NC, SAS Institute, 2010.
27. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS: Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157-172; discussion 207-212.
28. Raghu G, Meyer KC: Silent gastro-oesophageal reflux and microaspiration in IPF: mounting evidence for anti-reflux therapy? Eur Respir J 2012; 39: 242-245.
29. Lee JS, Collard HR, Anstrom KJ, Martinez FJ, Noth I, Roberts RS, Yow E, Raghu G; IPFnet Investigators: Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med 2013; 1: 369-376.
30. Lee JS, Ryu JH, Elicker BM, Lydell CP, Jones KD, Wolters PJ, King TE Jr, Collard HR: Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184: 1390-1394.
31. Raghu G, Yang ST, Spada C, Hayes J, Pellegrini CA: Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest 2006; 129: 794-800.
32. Linden PA, Gilbert RJ, Yeap BY, Boyle K, Deykin A, Jaklitsch MT, Sugarbaker DJ, Bueno R: Laparoscopic fundoplication in patients with end-stage lung disease awaiting transplantation. J Thorac Cardiovasc Surg 2006; 131: 438-446.
33. Myles PR, Hubbard RB, Gibson JE, Pogson Z, Smith CJ, McKeever TM: The impact of statins, ACE inhibitors and gastric acid suppressants on pneumonia mortality in a UK general practice population cohort. Pharmacoepidemiol Drug Saf 2009; 18: 697-703.
34. Ibrahim EH, Tracy L, Hill C, Fraser VJ, Kollef MH: The occurrence of ventilator-associated pneumonia in a community hospital: risk factors and clinical outcomes. Chest 2001; 120: 555-561.
35. Abramowitz J, Thakkar P, Isa A, Truong A, Park C, Rosenfeld RM: Adverse event reporting for proton pump inhibitor therapy: an overview of systematic reviews. Otolaryngol Head Neck Surg 2016; 155: 547-554.